4-溴-1H-吲哚-3-羧酸 | 110811-31-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-溴-1H-吲哚-3-羧酸
• 中文别名: 4-溴-1-叔丁氧羰基-1H-吲哚-3-羧酸
• 英文名称: 4-bromo-1H-indole-3-carboxylic acid
• CAS: 110811-31-9
• 化学式: C₉H₆BrNO₂
• mdl: MFCD09817565
• 分子量: 240.056
• InChiKey: GJQQLCJFHKJARJ-UHFFFAOYSA-N

物化性质

• 熔点：
  137-138
• 沸点：
  470.9±25.0 °C(Predicted)
• 密度：
  1.838±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	4-Bromo-1-(tert-butoxycarbonyl)-1H-indole-3-carboxylic acid Material Safety Data Sheet
Synonym:
CAS:	110811-31-9

Section 1 - Chemical Product MSDS Name:4-Bromo-1-(tert-butoxycarbonyl)-1H-indole-3-carboxylic acid Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
110811-31-9	4-Bromo-1-(tert-butoxycarbonyl)-1H-ind	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 110811-31-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: White
Odor: Characteristic odour
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 154 - 156 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H14BrNO4
Molecular Weight: 340.18

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids, strong bases.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 110811-31-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-1-(tert-butoxycarbonyl)-1H-indole-3-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 110811-31-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 110811-31-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 110811-31-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-1H-吲哚-3-羧酸 在 草酰氯 、 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) 、 水 、 potassium carbonate 、 caesium carbonate 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 41.0h， 生成 1-ethyl-4-[[4-(trifluoromethyl)phenyl]methyl]indole-3-carboxylic acid
  参考文献：
  名称：

  [EN] PROSTAGLANDIN E2 RECEPTOR 4 ANTAGONISTS AND USES THEREOF
  [FR] ANTAGONISTES DU RÉCEPTEUR 4 DE LA PROSTAGLANDINE E2 ET LEURS UTILISATIONS

  摘要：

  本文披露了一种用于调节前列腺素E2受体4（EP4）的化合物、组合物和方法，其中所披露的化合物和组合物。还描述了一种使用EP4拮抗剂治疗由前列腺素E2（PGE2）在前列腺素E2受体4（EP4）介导的疾病或紊乱的方法，如癌症。

  公开号：

  WO2020251957A1
• 作为产物：
  描述：

  1-(4-溴-1H-吲哚-3-基)-2,2,2-三氯乙酮 在 水 、 potassium hydroxide 、 盐酸 作用下， 以 乙醇 为溶剂， 反应 1.5h， 以59%的产率得到4-溴-1H-吲哚-3-羧酸
  参考文献：
  名称：

  Drug Design, in Vitro Pharmacology, and Structure−Activity Relationships of 3-Acylamino-2-aminopropionic Acid Derivatives, a Novel Class of Partial Agonists at the Glycine Site on the N-Methyl-d-aspartate (NMDA) Receptor Complex

  摘要：

  Retaining agonistic activity at the glycine coagonist site of the NMDA receptor in molecules derived from glycine or D-serine has proven to be difficult because in the vicinity of the alpha-amino acid group little substitution is tolerated. We have solved this problem by replacing the hydroxy group of D-serine with an amido group, thus keeping the hydrogen donor function and allowing For further substitution and exploration of the adjacent space. Heterocyclic substitutions resulted in a series of 3-acylamino-2-aminopropionic acid derivatives, with high affinities in a binding assay for the glycine site. In a functional assay assessing the activation of the glycine site, these compounds displayed a wide range of intrinsic efficacies, from antagonism to a high degree of partial agonism. Structure-activity relationships reveal that lipophilic substituents, presumably filling an additional hydrophobic pocket, are accepted by the glycine site, provided that they are separated from the alpha-amino acid group by a short linker.

  DOI：

  10.1021/jm900363q

文献信息

• Integrin expression inhibitors
  申请人：——

  公开号：US20040018192A1

  公开（公告）日：2004-01-29

  The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. 1 In the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

  本发明提供了一种整合素表达抑制剂，以及基于整合素抑制作用的用于治疗动脉硬化、银屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病的药剂、抗凝剂或癌症转移抑制剂。即提供了一种包含以下式(I)所表示的磺胺化合物、其药理学上可接受的盐或其水合物作为活性成分的整合素表达抑制剂。 在该式中，B表示一个C6-C10芳基环或6-至10成员杂芳基环，可能具有取代基，并且环的一部分可能是饱和的；K表示一个单键，-CH═CH-或-(CR 4b R 5b ) m b -（其中R 4b 和R 5b 相同或不同，各自表示氢原子或C1-C4烷基；m b 表示1或2的整数）；R 1 表示氢原子或C1-C6烷基；Z表示一个单键或-CO-NH-；R表示一个C6-C10芳基环或6-至10成员杂芳基环，可能具有取代基，并且环的一部分可能是饱和的，分别。
• QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY
  申请人：CoMentis, Inc.

  公开号：US20160009706A1

  公开（公告）日：2016-01-14

  Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.

  提供了替代性的喹诺啡啶化合物，包括这些化合物的药物组合物，以及使用这些化合物调节α7烟碱乙酰胆碱受体和治疗神经系统疾病的方法。
• [EN] BIS-INDOLIC DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG<br/>[FR] DÉRIVÉS BIS-INDOLIQUES, PROCÉDÉ POUR PRÉPARER CEUX-CI ET LEURS UTILISATIONS EN TANT QUE MÉDICAMENT
  申请人：UNIV JOSEPH FOURIER

  公开号：WO2013014102A1

  公开（公告）日：2013-01-31

  The present invention relates to novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.

  本发明涉及新型双吲哚衍生物、其制备方法以及它们作为新型抗菌药物的潜在用途。
• Studies on the Claisen rearrangements in the indolo[2,3-b]quinoline system
  作者：Nicholas Voûte、Douglas Philp、Alexandra M. Z. Slawin、Nicholas J. Westwood

  DOI：10.1039/b915677a

  日期：——

  A study of the effect of substrate structure on a Claisen-aza-Cope reaction is presented including a rationalisation of the reaction outcome using DFT calculations. An asymmetric version of the reaction is also described that is of relevance to a proposed approach to the communesin family of natural products.

  提出了对底物结构对Claisen-aza-Cope反应的影响的研究，包括使用DFT计算合理化反应结果。还描述了反应的不对称形式，其与天然产物共生素家族的拟议方法有关。
• [EN] HETEROARYL-SUBSTITUTED 2-PYRIDINYLMETHYLAMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 2-PYRIDINYLMÉTHYLAMINE SUBSTITUÉS PAR HÉTÉROARYLE
  申请人：UNIV FRIEDRICH ALEXANDER ER

  公开号：WO2009060030A1

  公开（公告）日：2009-05-14

  The present disclosure relates to compounds having the general formula (I) wherein Q represents a five membered heteroaryl group. The compoungs are selective 5-HT1 a modulators and are useful for treating several diseases.

  本公开涉及具有通式（I）的化合物，其中Q代表五元杂环芳基基团。这些化合物是选择性5-HT1a调节剂，可用于治疗多种疾病。